DOCSLIB.ORG

Method for Producing Monolithic Tablets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Method for Producing Monolithic Tablets (19) TZZ¥_ ZZ_T (11) EP 3 124 008 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 01.02.2017 Bulletin 2017/05 A61J 3/06 (2006.01) (21) Application number: 16189646.9 (22) Date of filing: 04.11.2011 (84) Designated Contracting States: • LEFEBVRE, Didier AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Mundelein, IL 60060 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • WIESNER, Bryan PL PT RO RS SE SI SK SM TR Lake Forest, IL 60045 (US) Designated Extension States: • BREITENBACH, Joerg BA ME 68199 Mannheim (DE) • KESSLER, Thomas (30) Priority: 04.11.2010 US 410344 P 67105 Schifferstadt (DE) (62) Document number(s) of the earlier application(s) in (74) Representative: Modiano, Micaela Nadia et al accordance with Art. 76 EPC: Modiano & Partners 11785864.7 / 2 635 247 Thierschstrasse 11 80538 München (DE) (71) Applicants: • AbbVie Inc. Remarks: North Chicago, IL 60064 (US) This application was filed on 20.09.2016 as a • AbbVie Deutschland GmbH & Co. KG divisional application to the application mentioned 65189 Wiesbaden (DE) under INID code 62. (72) Inventors: • GHOSH, Soumojeet Gurnee, IL 60031 (US) (54) METHOD FOR PRODUCING MONOLITHIC TABLETS (57) The present invention relates to a process for producing monolithic tablets. The method employs a melt-processed composition containing at least on active agent and at least one thermoplastic binder. The inven- tion further relates to a method for cutting and deflashing a belt of pre-shaped bodies of a melt-processed compo- sition, wherein the pre-shaped bodies are interconnected by flash. EP 3 124 008 A1 Printed by Jouve, 75001 PARIS (FR) 1 EP 3 124 008 A1 2 Description organism, flash or ridges might even be hazardous by injuring mouth cavities or esophagus or otherwise inter- Related Application Information fering with swallowing the tablet,. [0005] Consequently, the flash (e.g., burrs) have to be [0001] This application claims priority to U.S. Applica- 5 removed. Present methods comprise cutting off the flash, tion number 61/ 410,344 filed on November 4, 2010, the or reducing their volume by polishing the surface of the contents of which are herein incorporated by reference tablets by methods such as tumbling. However, cutting in their entirety. or tumbling may not be effective to completely remove disturbing flash or ridges, but rather leaves remnants Field of the Invention 10 thereof, soften visible as rough spots, on the surface. Moreover, in the case of tablets made from impact re- [0002] The present invention relates to methods for sistant materials, tumbling is ineffective. It is possible to producing monolithic tablets using melt-extrusion tech- cool down the tablets to temperatures, where the tablet nology. material becomes brittle enough to allow flash removal 15 by tumbling. However, performing the tumbling proce- Background dure at low temperature increases the danger of moisture condensation on the surface of the tablets, which may [0003] Various methods for producing tablets are affect the shape of the tablet, cause decomposition of known in the art. Widely used methods comprise starting the ingredients or affect the shelf life of the tablet. As materials in powder form, such as the active agent and 20 such effects are not acceptable, tumbling at low tempara- one or more additive. The starting materials are blended, tures requires a strict control of ambient moisture, thus and the obtained blend is compressed in a die between rendering the production of the tablets more difficult and the moving punches of a tablet press, yielding a tablet. more expensive. Therefore, there is a need for a method Other methods are based on a sequence of melting and for obtaining tablets having acceptably even tablet sur- solidification rather than compression. In these methods 25 faces. thermoplastic polymers serve as binders in the final tab- let. For the preparation of the tablets, the starting mate- Summary rials, including the thermoplastic binders, the active agents and optionally further additives are blended, heat- [0006] Surprisingly, in the present invention it was ed in an extruder to melt into a homogenous extrudate. 30 found that the problems mentioned above in the Back- The extrudate can be further processed to obtain the de- ground section can be avoided and tablets with superior sired shape and size of the tablet, for example by directly surface characteristics can be produced if an extrudate introducing the extrudate in a cavity of appropriate shape is compressed between punches of a tabletting press. (injection molding). Alternatively, the extrudate can be Specifically, the methods of the present invention allow expelled from the extruder and be shaped using calen- 35 for the control of the content uniformity of each unit dose dars, die cutter, and the like. of a solid dosage form. Content uniformity is the ability [0004] A disadvantage of methods requiring the shap- to deliver a dose in a repeatable manner according to ing of an extrudate lies in the fact, that the shaping step the US Pharmacopeia. The methods of the present in- leaves marks on the finished tablets. After calendering, vention provide flexibility in terms of providing dosage for example, the tablets may be connected by so-called 40 forms with having more conventional shapes that were flash (also referred as burrs) after separation. Even after not previously achievable using melt-extrusion tech- separating the tablets by additional processes such as niques. cutting the flash, it is difficult to completely remove them. [0007] In one embodiment, the present inventon re- Likewise, tablets formed by injection molding usually also lates to a method of producing a monolithic tablet. The have flash due to the fact that for release of the tablets 45 method comprises the steps of: the injection molding cavity must be opened. For that reason, the wall of the molding cavity is usually formed a) providing a melt-processed composition contain- by two or more partial walls, which form a closed cavity ing at least one active agent and at least one ther- during the shaping step, and are removed to release the moplastic binder; shaped tablet. Since it is difficult to create a perfectly50 b) charging a predetermined amount by weight of smooth surface in the regions, where the partial wall con- the melt-processed mixture into a die cavity; tact each other during the injection molding, extrudate c) compressing the melt-processed composition to can also enter those regions, leading to flash or at least simultaneously shape and (1C11iiS11 the composi- visible ridges ("burrs") on the surface of the finished tab- tion to form a monolithic tablet, using compression let. Flash or ridges, however, are aestheticafly inaccept- 55 equipment; and able, and might modify the release profile of the active d) ejecting the monolithic tablet from the die. agents, e.g. by altering the surface area or shape of the tablet. In case the tablet is to be swallowed by a higher [0008] Suitably, the (lie cavity is located between 2 3 EP 3 124 008 A1 4 punches within a tabletting press. [0024] In yet another aspect, the melt-processed com- [0009] In one aspect, the melt-processed composition position is reheated to a temperature at or above the is renderedplastically reformable byheating priorto com- softening temperature of the composition. pression. In another aspect, the melt-processed compo- [0025] In still yet another aspect, the die cavity or a sition does not need to be re-heated prior to compression. 5 feed system is provided with temperature control means. [0010] The melt-processed composition may comprise [0026] In yet another aspect, at least one punch has plastifying a composition containing at least one active an embossed or debossed die face. In a second embod- agent and at least one thermoplastic binder by heating iment, there is provided a method for producing mono- and/or shearing to obtain a melt, and forcing the melt lithic tablets. The method comprises the steps of: through at least one orifice. 10 [0011] Suitably, the melt-processed composition is a) providing a belt of pre-shaped bodies of a melt- manufactured by melt-extrusion or injection molding. processed composition, the pre-shaped bodies in [0012] In one aspect, particles of the melt-processed said belt being interconnected by flash, each pre- composition are fed gravimetrically or by pressure into shaped body having an predetermined weight, the die cavity. 15 b) cutting the interconnecting flash to obtain singu- [0013] Providing particles of the melt-processed com- lated or singular pre-shaped bodies, and position may comprise calendered pre-shaped lentils, c) compressing the singulated pre-shaped bodies to hot spheronization, cold pelletization, or clyo-milling. simultaneously shape and deflash to obtain mono- [0014] In another aspect, pre-shaped bodies of the lithic tablets. melt-processed composition are provided, each having 20 a predetermined weight, and a pre-determined number [0027] In the above method, lite cutting and deflashing of the pre-shaped bodies is charged into the die cavity. are performed sequentially. For example, the deflashing [0015] Inyet anotheraspect, the number of pre-shaped can be performed by placing the singular pre-shaped bodies to be charged into the die cavity is one. body into a compress to simultaneously shape and de- [0016] In still another aspect, providing pre-shaped 25 flaslt the body. Alternatively, in the above method, the bodies of the melt-processed mixture comprises a cal- cutting and deflashing are performed simultaneously. endering process. [0028] In the above method, the cutting and deflashing [0017] Providing pro-shaped bodies of the melt-proc- are performed using a means selected among mechan- essed mixture may comprise a calendering process to ical means, a laser beam or a water jet.
Load more

Recommended publications
  • TARIFF SCHEDULE of CHILE Description MFN Base Rate
    TARIFF SCHEDULE OF CHILE Tariff Line Description MFN Base rate Australia Brunei Canada Japan Malaysia Mexico New Peru Singapore US Vietnam (1 Jan 2010) Zealand 0101.10.00 -Pure-bred breeding animals 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0101.90.11 ---Race horses 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0101.90.19 ---Other 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0101.90.90 --Other 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0102.10.00 -Pure-bred breeding animals 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0102.90.00 -Other 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0103.10.00 -Pure-bred breeding animals 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0103.91.00 --Weighing less than 50 kg 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0103.92.00 --Weighing 50 kg or more 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0104.10.10 --Pure-bred breeding animals 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0104.10.90 --Other 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0104.20.00 -Goats 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0105.11.10 ---Breeding animals 6 EIF EIF B8 EIF EIF EIF EIF EIF EIF EIF EIF 0105.11.90 ---Other 6 EIF EIF B8 EIF EIF EIF EIF EIF EIF EIF EIF 0105.12.00 --Turkeys 6 EIF EIF B8 EIF EIF EIF EIF EIF EIF EIF EIF 0105.19.00 --Other 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF 0105.94.00 --Fowls of the species Gallus domesticus 6 EIF EIF B8 EIF EIF EIF EIF EIF EIF EIF EIF 0105.99.00 --Other 6 EIF EIF B8 EIF EIF EIF EIF EIF EIF EIF EIF 0106.11.00 --Primates 6 EIF EIF EIF EIF EIF EIF EIF EIF EIF EIF
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • ERJ-01090-2018.Supplement
    Shaheen et al Online data supplement Prescribed analgesics in pregnancy and risk of childhood asthma Seif O Shaheen, Cecilia Lundholm, Bronwyn K Brew, Catarina Almqvist. 1 Shaheen et al Figure E1: Data available for analysis Footnote: Numbers refer to adjusted analyses (complete data on covariates) 2 Shaheen et al Table E1. Three classes of analgesics included in the analyses ATC codes Generic drug name Opioids N02AA59 Codeine, combinations excluding psycholeptics N02AA79 Codeine, combinations with psycholeptics N02AA08 Dihydrocodeine N02AA58 Dihydrocodeine, combinations N02AC04 Dextropropoxyphene N02AC54 Dextropropoxyphene, combinations excluding psycholeptics N02AX02 Tramadol Anti-migraine N02CA01 Dihydroergotamine N02CA02 Ergotamine N02CA04 Methysergide N02CA07 Lisuride N02CA51 Dihydroergotamine, combinations N02CA52 Ergotamine, combinations excluding psycholeptics N02CA72 Ergotamine, combinations with psycholeptics N02CC01 Sumatriptan N02CC02 Naratriptan N02CC03 Zolmitriptan N02CC04 Rizatriptan N02CC05 Almotriptan N02CC06 Eletriptan N02CC07 Frovatriptan N02CX01 Pizotifen N02CX02 Clonidine N02CX03 Iprazochrome N02CX05 Dimetotiazine N02CX06 Oxetorone N02CB01 Flumedroxone Paracetamol N02BE01 Paracetamol N02BE51 Paracetamol, combinations excluding psycholeptics N02BE71 Paracetamol, combinations with psycholeptics 3 Shaheen et al Table E2. Frequency of analgesic classes prescribed to the mother during pregnancy Opioids Anti- Paracetamol N % migraine No No No 459,690 93.2 No No Yes 9,091 1.8 Yes No No 15,405 3.1 No Yes No 2,343 0.5 Yes No
    [Show full text]
  • Medicines Regulations 1984 (SR 1984/143)
    Reprint as at 1 July 2014 Medicines Regulations 1984 (SR 1984/143) David Beattie, Governor-General Order in Council At the Government House at Wellington this 5th day of June 1984 Present: His Excellency the Governor-General in Council Pursuant to section 105 of the Medicines Act 1981, and, in the case of Part 3 of the regulations, to section 62 of that Act, His Excellency the Governor-General, acting on the advice of the Minister of Health tendered after consultation with the organisations and bodies that ap- peared to the Minister to be representatives of persons likely to be substantially affected, and by and with the advice and consent of the Executive Council, hereby makes the following regulations. Contents Page 1 Title and commencement 5 Note Changes authorised by subpart 2 of Part 2 of the Legislation Act 2012 have been made in this official reprint. Note 4 at the end of this reprint provides a list of the amendments incorporated. These regulations are administered by the Ministry of Health. 1 Reprinted as at Medicines Regulations 1984 1 July 2014 2 Interpretation 5 Part 1 Classification of medicines 3 Classification of medicines 11 Part 2 Standards 4 Standards for medicines, related products, medical 11 devices, cosmetics, and surgical dressings 5 Pharmacist may dilute medicine in particular case 12 6 Colouring substances [Revoked] 12 Part 3 Advertisements 7 Advertisements not to claim official approval 13 8 Advertisements for medicines 13 9 Advertisements for related products 15 10 Advertisements for medical devices 15 11 Advertisements
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 1-(4-Amino-Cyclohexyl)
    (19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art.
    [Show full text]
  • Protocol for a Randomised Controlled Trial: Efficacy of Donepezil Against
    BMJ Open: first published as 10.1136/bmjopen-2013-003533 on 25 September 2013. Downloaded from Open Access Protocol Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP) Hideyuki Sawada, Tomoko Oeda To cite: Sawada H, Oeda T. ABSTRACT ARTICLE SUMMARY Protocol for a randomised Introduction: Psychosis, including hallucinations and controlled trial: efficacy of delusions, is one of the important non-motor problems donepezil against psychosis Strengths and limitations of this study in patients with Parkinson’s disease (PD) and is in Parkinson’s disease ▪ In previous randomised controlled trials for (EDAP). BMJ Open 2013;3: possibly associated with cholinergic neuronal psychosis the efficacy was investigated in patients e003533. doi:10.1136/ degeneration. The EDAP (Efficacy of Donepezil against who presented with psychosis and the primary bmjopen-2013-003533 Psychosis in PD) study will evaluate the efficacy of endpoint was improvement of psychotic symp- donepezil, a brain acetylcholine esterase inhibitor, for toms. By comparison, this study is designed to prevention of psychosis in PD. ▸ Prepublication history for evaluate the prophylactic effect in patients this paper is available online. Methods and analysis: Psychosis is assessed every without current psychosis. Because psychosis To view these files please 4 weeks using the Parkinson Psychosis Questionnaire may be overlooked and underestimated it is visit the journal online (PPQ) and patients with PD whose PPQ-B score assessed using a questionnaire, Parkinson (http://dx.doi.org/10.1136/ (hallucinations) and PPQ-C score (delusions) have Psychosis Questionnaire (PPQ) every 4 weeks. bmjopen-2013-003533). been zero for 8 weeks before enrolment are ▪ The strength of this study is its prospective randomised to two arms: patients receiving donepezil design using the preset definition of psychosis Received 3 July 2013 hydrochloride or patients receiving placebo.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Genl:VE 1970 © World Health Organization 1970
    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]